CLINICAL EVIDENCE — PROCEDURAL OUTCOMES TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI)

Indications, Safety, and Warnings   Indications, Safety, and Warnings 

OUTSTANDING PROCEDURAL PERFORMANCE

The latest study results demonstrate excellent procedural performance.

EVOLUT PRO STUDY1

The Evolut PRO Study is a prospective, multicenter, non-randomized, single-arm study. Primary safety endpoints were all-cause mortality and disabling stroke at 30 days, and the primary efficacy endpoint was percentage of patients with no or trace aortic regurgitation at 30 days.

  • Study Status/Duration: 1-year outcomes reported/
    5-year follow-up
  • Sample Size: N = 60
  • Devices: Evolut PRO TAV
DOWNLOAD Data

Pro PVL Data

SURTAVI CONTINUED ACCESS STUDY2

Patients underwent attempted TAV implant under the same inclusion and exclusion criteria and trial procedures as the SURTAVI Trial, with no randomization to surgery.

  • Study Status/Duration: 30-day outcomes reported/5-year follow-up
  • Sample Size: N = 275
  • Devices: Evolut R 93%/CoreValve 7%, TAV
SEE DATA

Surtavi CAS 30 days

See the Medtronic TAVI Clinical Evidence Compendium for additional study results.

TAVI CLINICAL GUIDELINES

Find here the latest ESC/EACTS Valve Heart Disease Guidelines.

FIND NOW

STAY

INFORMED

Receive email updates about Medtronic TAVI.

SIGN UP

MEDTRONIC ACADEMY

View more clinical data and access procedural resources.

LOG IN OR REGISTER
1

Williams, as presented in poster at ACC.18

2

Van Mieghem N, et al. Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients: 1-Year Results from the SURTAVI Clinical Trial. Presented at TCT 2017.